MoneyWorks4Me

Suven Pharmaceuticals acquires 56% stake in NJ Bio

21 Dec 2024 Evaluate

Suven Pharmaceuticals has acquired 56% equity share capital of NJ Bio, Inc., at an aggregate consideration of $64.4 million, which includes $15 million of primary equity infusion into the NJ Bio. Therefore, the acquisition of 56% equity share capital of NJ Bio by the company has been completed on December 20, 2024.

Suven Pharmaceuticals is India’s leading technology-focused CDMO, offering integrated solutions in custom synthesis, process R&D, and manufacturing for global innovators.


Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..